{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T12:03:45Z","timestamp":1783771425135,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":285,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019759","name":"Wallace Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019759","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013057","name":"Heffter Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.neuropharm.2022.109166","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T13:00:44Z","timestamp":1655384444000},"page":"109166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Psychedelics as preventive treatment in headache and chronic pain disorders"],"prefix":"10.1016","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7962-0365","authenticated-orcid":false,"given":"Emmanuelle A.D.","family":"Schindler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2022.109166_bib1","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12954-017-0186-6","article-title":"Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches","volume":"14","author":"Andersson","year":"2017","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.neuropharm.2022.109166_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrn3516","article-title":"Cognitive and emotional control of pain and its disruption in chronic pain","volume":"14","author":"Bushnell","year":"2013","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109166_bib3","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2022.109166_bib4","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1177\/0333102418804160","article-title":"Increased use of illicit drugs in a Dutch cluster headache population","volume":"39","author":"de Coo","year":"2019","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2022.109166_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1177\/0333102415583145","article-title":"The use of illicit drugs as self-medication in the treatment of cluster headache: results from an Italian online survey","volume":"36","author":"Di Lorenzo","year":"2016","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2022.109166_bib6","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1526-4610.1977.hed1703118.x","article-title":"Brief report: phantom limp pain: sub-hallucinogenic treatment with lysergic acid diethylamide (LSD-25)","volume":"17","author":"Fanciullacci","year":"1977","journal-title":"Headache"},{"key":"10.1016\/j.neuropharm.2022.109166_bib7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","article-title":"Psychedelics as anti-inflammatory agents","volume":"30","author":"Flanagan","year":"2018","journal-title":"Int. Rev. Psychiatr."},{"key":"10.1016\/j.neuropharm.2022.109166_bib8","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1532-2149.2013.00433.x","article-title":"Mirror therapy for phantom limb pain: brain changes and the role of body representation","volume":"18","author":"Foell","year":"2014","journal-title":"Eur. J. Pain"},{"key":"10.1016\/j.neuropharm.2022.109166_bib9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000467984","article-title":"LSD-assisted psychotherapy in patients with terminal cancer","volume":"8","author":"Grof","year":"1973","journal-title":"Int. Pharmacopsychiatr."},{"key":"10.1016\/j.neuropharm.2022.109166_bib10","first-page":"1","article-title":"Can psychedelics alleviate symptoms of cluster headache and accompanying mental health problems? A case report involving Hawaiian baby woodrose","author":"Johnson","year":"2020","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2022.109166_bib11","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1177\/0333102410363490","article-title":"The non-hallucinogen 2-bromo-lysergic acid diethylamide as preventative treatment for cluster headache: an open, non-randomized case series","volume":"30","author":"Karst","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.neuropharm.2022.109166_bib12","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/BF01575629","article-title":"Attenuation of anticipation: a therapeutic use of lysergic acid diethylamide","volume":"41","author":"Kast","year":"1967","journal-title":"Psychiatr. Q."},{"key":"10.1016\/j.neuropharm.2022.109166_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1080\/02791072.1985.10524332","article-title":"LSD in the supportive care of the terminally ill cancer patient","volume":"17","author":"Kurland","year":"1985","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2022.109166_bib14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)32497-3","article-title":"Dual actions of lysergic acid diethylamide tartrate (LSD), 2-bromo-D-lysergic acid diethylamide bitartrate (BOL) and methysergide on dorsal root potentials evoked by stimulation of raphe nuclei","volume":"217","author":"Larson","year":"1981","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109166_bib15","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics promote structural and functional neural plasticity","volume":"23","author":"Ly","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.neuropharm.2022.109166_bib16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jnnp.2003.024240","article-title":"Verapamil induced gingival enlargement in cluster headache","volume":"76","author":"Matharu","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.neuropharm.2022.109166_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1152\/jn.00457.2012","article-title":"Theories of pain: from specificity to gate control","volume":"109","author":"Moayedi","year":"2013","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2022.109166_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/cpt.557","article-title":"Psychedelics as medicines: an emerging new paradigm","volume":"101","author":"Nichols","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2022.109166_bib19","first-page":"144","article-title":"LSD-assisted psychotherapy with terminal cancer patients","volume":"9","author":"Pahnke","year":"1969","journal-title":"Curr. Psychiatr. Ther."},{"key":"10.1016\/j.neuropharm.2022.109166_bib20","series-title":"Treatment of Cluster Headache Symptoms Using Synthetic Tryptamine N,N-diallyl-5 Methoxytryptamine","author":"Post","year":"2014"},{"key":"10.1016\/j.neuropharm.2022.109166_bib21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1080\/13554794.2018.1468469","article-title":"Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF)","volume":"24","author":"Ramachandran","year":"2018","journal-title":"Neurocase"},{"key":"10.1016\/j.neuropharm.2022.109166_bib22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0269881120940937","article-title":"A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers","volume":"35","author":"Ramaekers","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2022.109166_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020835","article-title":"A single dose of psilocybin increases synaptic density and decreases 5-ht2a receptor density in the pig brain","volume":"22","author":"Raval","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2022.109166_bib24","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1080\/02791072.2015.1107664","article-title":"Indoleamine hallucinogens in cluster headache: results of the Clusterbusters medication use survey","volume":"47","author":"Schindler","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"10.1016\/j.neuropharm.2022.109166_bib25","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s13311-020-00962-y","article-title":"Exploratory controlled study of the migraine-suppressing effects of psilocybin","volume":"18","author":"Schindler","year":"2021","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.neuropharm.2022.109166_bib26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fphar.2018.00177","article-title":"Neuroendocrine associations underlying the persistent therapeutic effects of classic serotonergic psychedelics","volume":"9","author":"Schindler","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109166_bib27","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1212\/01.wnl.0000219761.05466.43","article-title":"Response of cluster headache to psilocybin and LSD","volume":"66","author":"Sewell","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2022.109166_bib28","series-title":"Prophylactic Treatment of Migraine by Means of Lysergic Acid Derivatives","first-page":"116","author":"Sicuteri","year":"1963"},{"key":"10.1016\/j.neuropharm.2022.109166_bib29","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2217\/pmt-2017-0068","article-title":"Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role?","volume":"8","author":"Whelan","year":"2018","journal-title":"Pain Manag."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:18:33Z","timestamp":1758439113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":29,"alternative-id":["S0028390822002258"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109166","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychedelics as preventive treatment in headache and chronic pain disorders","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109166"}}